CyclopharmASX:CYC 46 Gross Margin % is -4,123.12% as of Dec. 2025. GuruFocus rates ASX:CYC with a GF Score™ of 46/100 and a GF Value™ of A$0.84 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 116 Medical Distribution companies, Cyclopharm ranks worse than 53.45% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Cyclopharm's Gross Profit for the
six
months ended in Dec. 2025 was A$-7.13 Mil. Cyclopharm's Revenue for the
six
months ended in Dec. 2025 was A$0.17 Mil. Therefore, Cyclopharm's Gross Margin % for the quarter that ended in Dec. 2025 was -4,123.12%.
Warning Sign:
Cyclopharm Ltd gross margin has been in long-term decline. The average rate of decline per year is -22.5%.
The historical rank and industry rank for Cyclopharm's Gross Margin % or its related term are showing as below:
ASX:CYC'
s Gross Margin % Range Over the Past 10 Years
Min: 13.3 Med: 72.26 Max: 79.92
Current: 13.3
During the past 13 years, the highestGross Margin % of Cyclopharm was 79.92%. The lowest was 13.30%. And the median was 72.26%.
ASX:CYC's Gross Margin % is ranked worse than 53.45% of 116
companies
in the Medical Distribution industry
Industry Median: 14.9
vs ASX:CYC: 13.30
Cyclopharm had a gross margin of -4,123.12% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Cyclopharm was -22.50% per year.
Cyclopharm (ASX:CYC) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cyclopharm had a gross margin of -4,123.12% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Cyclopharm Gross Margin % Related Terms
Cyclopharm Gross Margin % Historical Data
* Premium members only.
The historical data trend for Cyclopharm's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CYC vs MCK, COR, CAH: Gross Margin % Comparison
For the Medical Distribution subindustry, Cyclopharm's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclopharm Gross Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cyclopharm's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Cyclopharm's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Cyclopharm (ASX:CYC) has a Gross Margin % of -4,123.12% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Cyclopharm and its competitors. Over the past decade, Cyclopharm's Gross Margin % has ranged from 13.30 to 79.92. According to the industry distribution chart, Cyclopharm ranks #62 out of 116 companies in the Medical Distribution industry, placing it in the top 53.4%.
Is Cyclopharm's Gross Margin % too high?
Cyclopharm's current Gross Margin % is -4,123.12%. Over the past 10 years, this metric has ranged from a low of 13.30 to a high of 79.92. Based on the distribution chart, Cyclopharm ranks #62 out of 116 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Cyclopharm has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's Gross Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Cyclopharm ranks #62 out of 116 companies for Gross Margin %. This places Cyclopharm in the lower half of its industry. The industry median Gross Margin % is 14.90. Historically, Cyclopharm's own Gross Margin % has ranged from 13.30 to 79.92 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Distribution company?
The median Gross Margin % among Medical Distribution companies is 14.90, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Cyclopharm and its competitors. For the Medical Distribution industry, the median Gross Margin % is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclopharm's current Gross Margin % is -4,123.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.50 — trading 40.5% below its estimated fair value. The current Gross Margin % is -4,123.12%. Cyclopharm's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current Gross Margin % is -4,123.12% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyclopharm (ASX:CYC) Overvalued in 2026?
Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued.
The current stock price of A$0.50 is trading 40.5% below its estimated GF Value™ of A$0.84.
GuruFocus considers Cyclopharm to be Possible Value Trap.
Key valuation signals for ASX:CYC:
Gross Margin %: -4,123.12%
GF Value™: A$0.84 vs. price of A$0.50 (40.5% below fair value)
No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
46GF Score
Get the complete analysis for ASX:CYC
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYC has been successfully added to your 
